UNICA IRIS Institutional Research Information System

SERPE, ROBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 102.314
NA - Nord America 7.611
AS - Asia 2.564
SA - Sud America 429
Continente sconosciuto - Info sul continente non disponibili 206
AF - Africa 64
OC - Oceania 6
AN - Antartide 1
Totale 113.195
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 100.552
US - Stati Uniti d'America 7.488
CN - Cina 1.014
SG - Singapore 914
UA - Ucraina 497
SE - Svezia 377
BR - Brasile 334
DE - Germania 257
VN - Vietnam 224
GB - Regno Unito 183
FI - Finlandia 176
FR - Francia 131
HK - Hong Kong 78
CA - Canada 69
KR - Corea 64
IN - India 57
AR - Argentina 39
BD - Bangladesh 34
TR - Turchia 25
PK - Pakistan 23
RU - Federazione Russa 22
ZA - Sudafrica 21
IQ - Iraq 19
BE - Belgio 18
MX - Messico 17
IR - Iran 16
JP - Giappone 16
PL - Polonia 16
EC - Ecuador 15
ES - Italia 15
ID - Indonesia 15
PH - Filippine 14
KE - Kenya 12
NL - Olanda 12
CO - Colombia 10
MA - Marocco 10
IE - Irlanda 9
AT - Austria 8
JM - Giamaica 8
SA - Arabia Saudita 8
CH - Svizzera 7
CR - Costa Rica 7
EG - Egitto 7
EU - Europa 7
RS - Serbia 7
VE - Venezuela 7
AU - Australia 6
BG - Bulgaria 6
JO - Giordania 6
TN - Tunisia 6
BO - Bolivia 5
CL - Cile 5
LT - Lituania 5
NI - Nicaragua 5
PE - Perù 5
UY - Uruguay 5
UZ - Uzbekistan 5
DO - Repubblica Dominicana 4
PR - Porto Rico 4
PY - Paraguay 4
RO - Romania 4
KG - Kirghizistan 3
KZ - Kazakistan 3
LB - Libano 3
MY - Malesia 3
TH - Thailandia 3
AE - Emirati Arabi Uniti 2
AM - Armenia 2
DZ - Algeria 2
EE - Estonia 2
GT - Guatemala 2
IL - Israele 2
LA - Repubblica Popolare Democratica del Laos 2
PA - Panama 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
AL - Albania 1
AQ - Antartide 1
AZ - Azerbaigian 1
BB - Barbados 1
BS - Bahamas 1
BW - Botswana 1
BY - Bielorussia 1
GA - Gabon 1
GD - Grenada 1
GQ - Guinea Equatoriale 1
HU - Ungheria 1
IS - Islanda 1
KH - Cambogia 1
KW - Kuwait 1
LU - Lussemburgo 1
ME - Montenegro 1
MK - Macedonia 1
ML - Mali 1
MM - Myanmar 1
MO - Macao, regione amministrativa speciale della Cina 1
NG - Nigeria 1
NO - Norvegia 1
NP - Nepal 1
PS - Palestinian Territory 1
Totale 112.993
Salva come PNG Salva come JPEG
Città #
Cagliari 98.864
Uta 1.364
Ashburn 900
Woodbridge 600
Fairfield 577
Singapore 452
Dallas 410
San Jose 410
Houston 402
Chandler 390
Ann Arbor 316
Jacksonville 285
Boardman 274
Nyköping 268
Wilmington 251
Seattle 237
Beijing 235
Dearborn 171
Cambridge 170
Los Angeles 105
Helsinki 96
New York 93
Santa Clara 89
Nanjing 86
Ho Chi Minh City 80
Boston 79
Council Bluffs 75
Lauterbourg 73
Hefei 69
Hong Kong 69
Seoul 57
Shanghai 57
The Dalles 49
San Diego 47
Hanoi 45
São Paulo 42
Milan 37
Buffalo 36
Toronto 36
Nanchang 35
Munich 32
Redwood City 32
Guangzhou 29
Changsha 28
Atlanta 24
Tianjin 24
Hebei 22
Shenyang 22
London 21
Jinan 20
Verona 19
Brussels 16
Chicago 16
Phoenix 16
Redondo Beach 16
Norwalk 15
Tokyo 15
Chennai 14
Mountain View 14
Orange 14
Orem 14
San Francisco 14
Warsaw 14
Zhengzhou 14
Auburn Hills 13
Frankfurt am Main 13
Baghdad 12
Brooklyn 12
Rome 12
Washington 12
Nairobi 11
Philadelphia 11
Jiaxing 10
Sassari 10
Waltham 10
Montreal 9
Wuhan 9
Augusta 8
Charlotte 8
Columbus 8
Da Nang 8
Denver 8
Dong Ket 8
Dublin 8
Hangzhou 8
Johannesburg 8
Naples 8
Rio de Janeiro 8
Shenzhen 8
Thái Nguyên 8
Campinas 7
Haiphong 7
Kingston 7
Manchester 7
Nuremberg 7
Nürnberg 7
Pune 7
Quito 7
San Mateo 7
Stockholm 7
Totale 108.714
Salva come PNG Salva come JPEG
Nome #
High-density lipoprotein contribute to G0-G1/S transition in Swiss NIH/3T3 fibroblasts 4.994
Morningness Eveningness Questionnaire (MEQ) and salivary DLMO determination: a reliable method of evaluation for circadian pattern 3.753
Effects of an adapted physical training on functional status, body composition and quality of life in persons with spinal cord injury paraplegia: a pilot study 3.458
Krill Oil supplementation modifies endocannabinoid congeners profile in cachectic advanced cancer patients 3.383
Antimicrobial sulfonamides clear latent Kaposi sarcoma herpesvirus infection and impair MDM2-p53 complex formation 3.322
Cardiovascular effects, body composition, quality of life and pain after a Zumba® fitness program in Italian overweight women 3.178
Effects of a nordic walking program on motor and non-motor symptoms, functional performance and body composition in patients with Parkinson's disease 2.779
Antimicrobial sulfonamides inhibit Herpesvirus 8 latency by impairing the MDM2-p53 complex formation 2.725
Positive effects of Nordic Walking on anthropometric and metabolic variables in women with type 2 diabetes mellitus 2.707
Sulfonamide compounds inhibit latent Human Herpesvirus 8 replication by interfering with MDM2-p53 complex formation 2.557
Randomized phase III clinical trial of a combined treatment with carnitine plus celecoxib +/- megestrol acetate for patients with cancer-related anorexia/cachexia syndrome 2.445
Effects of an adapted physical activity program on motor and non-motor functions and quality of life in patients with Parkinson's disease 2.375
Selenium is effective in inducing lymphocyte progression through cell cycle in cancer patients: potential mechanisms for its activity 2.213
The cachexia score (CASCO) as a tool for staging cachectic cancer patients 2.212
null 2.211
Relationship of morningness-eveningness questionnaire score to Melatonin DLMO measured from saliva sample: circadian patterns of a normal subjects group and a delayed phase syndrome 2.137
Validation of the CAchexia SCOre (CASCO). Staging cancer patients: The use of miniCASCO as a simplified tool 2.101
Trastuzumab-based adjuvant chemotherapy for breast cancer: Early myocardial dysfunction detected by "speckle tracking" echocardiography (STE). 2.096
null 1.987
Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia 1.909
Krill oil to improve blood lipids status in advanced cancer patient with cachexia 1.794
Efficacy and safety of a two drug-combination regimen for cancer-related cachexia in the clinical practice. 1.742
Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia 1.731
Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results 1.727
Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy 1.708
null 1.699
Persistence, up to 18 months of follow-up, of epirubicin-induced myocardial dysfunction detected early by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers 1.684
Interleukin-1B (IL1B) and interleukin-6 (IL6) gene polymorphisms are associated with risk of chronic lymphocytic leukaemia 1.677
Production of inflammatory molecules in peripheral blood mononuclear cells from severely glucose-6-phosphate dehydrogenase-deficient subjects 1.603
Cardioprotective effect of telmisartan in cancer patients treated with telmisartan 1.532
L-Carnitine: An adequate supplement for a multi-targeted anti-wasting therapy in cancer 1.528
Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers 1.495
Trastuzumab-induced early cardiac dysfunction assessed by speckle tracking echocardiography: correlation with chronic inflammation and oxidative stress markers 1.489
Assessment of adiponectin and leptin as biomarkers of positive metabolic outcomes after lifestyle intervention in overweight and obese children 1.380
null 1.362
EFFICACY AND SAFETY OF A TWO DRUG-COMBINATION REGIMEN FOR CANCER-RELATED CACHEXIA IN THE CLINICAL PRACTICE 1.338
null 1.063
Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress 859
Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters 839
Association of serum IL-6 levels with comprehensive geriatric assessment variables in a population of elderly cancer patients 810
Cardioprotective effect of telmisartan in cancer patients treated with epirubicin 803
A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress 802
A PHASE II STUDY WITH ANTIOXIDANTS, BOTH IN THE DIET AND SUPPLEMENTED, PHARMACO-NUTRITIONAL SUPPORT,PROGESTAGEN AND ANTI-COX-2 SHOWING EFFICACY AND SAFETY IN PATIENTS WITH CANCER-RELATED ANOREXIA-CACHEXIA AND OXIDATIVE STRESS 799
Cancer-related anorexia/cachexia syndrome and oxidative stress: an innovative approach beyond current treatment 793
Antioxidant agents alpha lipoic acid, N-Acetyl cysteine and MESNA (2-mercaptoethane sulfonate) are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients 782
null 768
Early epirubicin-induced myocardail dysfunction revealed by serial tissue doppler echocardiography (TDI). Correlation with inflammatory and oxidative stress markers 748
Cardioprotective effect of Telmisartan in cancer patients treated with Epirubicin 747
Formoterol and cancer muscle wasting in rats: Effects on muscle force and total physical activity 743
Early epirubicin (EPI)-induced myocardial dysfunction revealed by serial tissue doppler imaging (TDI): Correlation with inflammatory and oxidative stress markers 741
Current medications for cancer cachexia 740
Cancer cachexia: Physical activity and muscle force in tumour-bearing rats 725
null 709
Muscle wasting in cancer and ageing: Cachexia versus sarcopenia 694
null 694
Improvement of physical activity as an alternative objective variable to measure treatment effects of anticachexia therapy in cancer patients 687
Randomised Phase III Clinical Trial of a Combined Treatment With Carnitine plus Celecoxib +/- Megestrol Acetate for Patients With Cancer-related Anorexia/cachexia Syndrome 671
The cachexia score (CASCO): a new tool for staging cachectic cancer patients 671
Megestrol acetate: Its impact on muscle protein metabolism supports its use in cancer cachexia 590
Randomised phase III clinical trial of 5 different arms of treatment for patients with cancer-related anorexia/cachexia syndrome (CACS): Interim results 582
A phase II study with antioxidants, pharmaco-nutritional support, progestagen and anti-COX-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia (CACS) and oxidative stress (OS) 581
null 572
Antioxidant therapy for the treatment of oxidative stress associated to cancer and cancer-related anorexia/cachexia 570
Phase II study with antioxidants, both in the diet and supplemented pharmaco-nutritional support, progestagen and anti-cox-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia (CACS) and oxidative stress (OS) 554
A phase II study with antioxidants, both in the diet an supplemented, pharmaco-nutritional support, progestagen and anti-COX-2 showing efficacy and safety in patients with cancer-related anorexia-cachexia and oxidative stress 553
Cancer related anorexia/cachexia (CACS) and oxidative stress: an innovative approach beyond current treatment 542
Cancer related anorexia/cachexia (CACS) and oxidative stress: an innovative approach beyond current treatment 537
Effects Of An Adapted Physical Training On Functional And Psycho-physical Status In Patients With Spinal Cord Injury 533
An innovative approach to CACS 518
Correlation between both serum osteopontin/osteonectin and bone remodelling parameters, inflammatory/metabolic variables and survival in metastatic cancer patients with tumors at different sites 517
Phase II study with antioxidants, pharmaco-nutritional support, progestagen and anti-COX-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia (CACS). and oxidative stress (OS) 515
Prevention of head and neck squamous cell carcinoma. Integrated treatment approach with diet, pharmaco-nutritional support, antioxidants, and cis-retinoic acid. A phase II study. 506
Prevention of head and neck squamous cell carcinoma. integrated treatment approach with diet, pharmaco-nutritional support, antioxidants (and anti-COX-2): preliminary results of a phase II study 485
null 465
null 450
Randomised phase III clinical trial of 5 different arms of treatment for patients with cancer-related anorexia/cachexia syndrome (CACS) 430
Efficacy of L-carnitine administration on fatigue, quality of life and nutritional status in 12 advanced cancer patients undergoing anticancer therapy 428
Randomised phase III clinical trial to evaluate the efficacy and safety of an integrated treatment (diet, pharmaco-nutrional and pharmacological) in cancer patients with cancer-related anorexia/cachexia and oxidative stress: interim results 420
null 413
null 390
Randomised phase III clinical trial to evaluate the efficacy and safety of an integrated treatment (diet, pharmaco-nutritional and pharmacological) in cancer patients with cancer-related anorexia/cachexia and oxidative stress: Interim results 348
Impact of a two-drug combination regimen for cancer-related cachexia on nutritional, anabolic/metabolic, physical activity, anti-infammatory and quality of life variables 343
null 342
An innovative treatment approach for cancer-related anorexia/cachexia and oxidative stress: Background and design of an ongoing, phase III, randomized clinical trial 342
Curcuma Longa extract is effective in improving inflammatory status and redox balance in patients with cancer-related cachexia and oxidative stress 331
Randomised phase III clinical trial of 5 different arms of treatment for patients with cancer-related anorexia/cachexia syndrome (CACS): Interim results 318
MESNA (2-mercaptoethane sulfonate) is effective in inducing lymphocyte progression through cell cycle in patients with advanced cancer of different sites 315
null 304
null 267
An innovative treatment approach for cancer-related anorexia/cachexia (CACS) and oxidative stress (OS). A phase III randomised clinical trial 263
Randomised phase III clinical trial of 5 different arms of treatment for patients with cancer-related anorexia/cachexia syndrome (CACS) 260
An innovative treatment approach for cancer-related anorexia/cachexia (CACS) and oxidative stress (OS) 228
Prognostic role of lipid profile in patients with advanced cancer 220
null 208
A phase II study with antioxidants, pharmaco-nutritional support, progestagen and anti-COX-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia (CACS) and oxidative stress (OS) 172
Cancer related anorexia/cachexia and oxidative stress: A phase II study with antioxidants, pharmaco-nutritional support, progestagen and anti-COX-2 170
Cancer-related anorexia/cachexia (CACS) and oxidative stress (OS): A phase II study with antioxidants, pharmaco-nutritional support, progestagen and anti-COX-2 159
Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia 154
Focus on the assessment of physical activity level of patients with cancer cachexia enrolled in a randomized phase III clinical trial 149
null 147
Totale 113.110
Salva come PNG Salva come JPEG
Categoria #
all - tutte 150.784
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 150.784
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.368 0 0 0 296 465 341 175 187 353 439 550 562
2022/20235.508 491 659 689 447 465 528 254 459 355 379 464 318
2023/20246.816 445 336 335 511 693 1.312 839 473 311 467 584 510
2024/20258.457 1.040 1.647 1.329 1.267 700 1.116 564 104 185 126 184 195
2025/20264.855 300 238 677 435 347 310 717 219 358 640 266 348
2026/20271.412 58 263 509 582 0 0 0 0 0 0 0 0
Totale 113.195